2500 Stock Overview
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally.
Venus Medtech (Hangzhou) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$17.50|
|52 Week High||HK$66.25|
|52 Week Low||HK$10.52|
|1 Month Change||29.44%|
|3 Month Change||17.14%|
|1 Year Change||-73.26%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-59.35%|
Recent News & Updates
|2500||HK Medical Equipment||HK Market|
Return vs Industry: 2500 underperformed the Hong Kong Medical Equipment industry which returned -58.8% over the past year.
Return vs Market: 2500 underperformed the Hong Kong Market which returned -20.3% over the past year.
|2500 Average Weekly Movement||11.2%|
|Medical Equipment Industry Average Movement||9.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in HK Market||13.7%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 2500 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 2500's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company’s products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension.
Venus Medtech (Hangzhou) Fundamentals Summary
|2500 fundamental statistics|
Is 2500 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2500 income statement (TTM)|
|Cost of Revenue||CN¥91.52m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.85|
|Net Profit Margin||-89.85%|
How did 2500 perform over the long term?See historical performance and comparison
Is 2500 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2500?
Other financial metrics that can be useful for relative valuation.
|What is 2500's n/a Ratio?|
Price to Sales Ratio vs Peers
How does 2500's PS Ratio compare to its peers?
|2500 PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
1858 Beijing Chunlizhengda Medical Instruments
1696 Sisram Medical
2160 MicroPort CardioFlow Medtech
1789 AK Medical Holdings
2500 Venus Medtech (Hangzhou)
Price-To-Sales vs Peers: 2500 is expensive based on its Price-To-Sales Ratio (15.7x) compared to the peer average (11.5x).
Price to Earnings Ratio vs Industry
How does 2500's PE Ratio compare vs other companies in the HK Medical Equipment Industry?
Price-To-Sales vs Industry: 2500 is expensive based on its Price-To-Sales Ratio (15.7x) compared to the Hong Kong Medical Equipment industry average (6.9x)
Price to Sales Ratio vs Fair Ratio
What is 2500's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||15.7x|
|Fair PS Ratio||13.1x|
Price-To-Sales vs Fair Ratio: 2500 is expensive based on its Price-To-Sales Ratio (15.7x) compared to the estimated Fair Price-To-Sales Ratio (13.1x).
Share Price vs Fair Value
What is the Fair Price of 2500 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2500's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2500's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2500's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Venus Medtech (Hangzhou) forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2500 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2500 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2500 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2500's revenue (30.1% per year) is forecast to grow faster than the Hong Kong market (10.1% per year).
High Growth Revenue: 2500's revenue (30.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2500 is forecast to be unprofitable in 3 years.
Discover growth companies
How has Venus Medtech (Hangzhou) performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2500 is currently unprofitable.
Growing Profit Margin: 2500 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2500 is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare 2500's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2500 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (35.4%).
Return on Equity
High ROE: 2500 has a negative Return on Equity (-8.02%), as it is currently unprofitable.
Discover strong past performing companies
How is Venus Medtech (Hangzhou)'s financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 2500's short term assets (CN¥3.4B) exceed its short term liabilities (CN¥208.5M).
Long Term Liabilities: 2500's short term assets (CN¥3.4B) exceed its long term liabilities (CN¥269.1M).
Debt to Equity History and Analysis
Debt Level: 2500 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2500's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2500 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 2500 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 30.7% each year
Discover healthy companies
What is Venus Medtech (Hangzhou) current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2500's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2500's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2500's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2500's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2500 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Eric Zi (52 yo)
Mr. Zhenjun Zi, also known as Eric, is Founder and Managing Partner at DiNovA Venture Capital. Prior to this, Mr. Zi served as Business Development & Strategic Planning Director at Lifetech Scientific Corp...
Experienced Management: 2500's management team is considered experienced (2.3 years average tenure).
Experienced Board: 2500's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Venus Medtech (Hangzhou) Inc.'s employee growth, exchange listings and data sources
- Name: Venus Medtech (Hangzhou) Inc.
- Ticker: 2500
- Exchange: SEHK
- Founded: 2009
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: HK$7.663b
- Shares outstanding: 437.90m
- Website: https://www.venusmedtech.com
Number of Employees
- Venus Medtech (Hangzhou) Inc.
- No. 88, Jiangling Road
- 3rd Floor
- Zhejiang Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/02 00:00|
|End of Day Share Price||2022/06/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.